Comparison of PD-L1 IHC 22C3 pharmDx Combined Positive Score in Primary vs. Metastatic Nodal Squamous Cell Carcinomas of the Head and Neck: Is There a Significant Difference?

被引：0
|
作者：
Surucu, Ahmet [1 ]
Hou, Tieying [1 ]
Durm, Gregory [1 ]
Corrales, Hector Mesa [1 ]
机构：
[1] Indiana Univ Sch Med, Indianapolis, IN USA
来源：
LABORATORY INVESTIGATION | 2023年 / 103卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1055
引用
收藏
页码：S1073 / S1074
页数：2
相关论文
共 50 条
  • [1] Comparison of PD-L1 IHC 22C3 PharmDx Combined Positive Score (CPS) in Primary Versus Metastatic Nodal Squamous Cell Carcinomas of the Head and Neck: Is There a Significant Difference?
    Surucu, Ahmet
    Hou, Tieying
    Kuhar, Matthew
    Durm, Greg
    Mesa, Hector
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2023, 31 (08) : 550 - 554
  • [2] Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx.
    Kulangara, Karina
    Hanks, Debra Ann
    Waldroup, Stephanie
    Peitz, Lindsay
    Shah, Supriya
    Roach, Charlotte
    Juco, Jonathan Wes
    Emancipator, Kenneth
    Stanforth, Dave
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] PD-L1 IHC 22C3 pharmDx helps determine first-line pembrolizumab eligibility in head and neck squamous cell carcinoma patients
    La Placa, C.
    Watts, B.
    Vilardo, M.
    Polewski, M.
    Tabuena-Frolli, S.
    Jansson, M.
    Juco, J.
    Emancipator, K.
    Jin, F.
    Gumuscu, B.
    Ge, J.
    Kulangara, K.
    VIRCHOWS ARCHIV, 2020, 477 : S79 - S79
  • [4] Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications
    Vainer, Gilad
    Huang, Lingkang
    Emancipator, Kenneth
    Nuti, Shanthy
    PLOS ONE, 2023, 18 (06):
  • [5] High concordance of the PD-L1 22C3 antibody LDT protocol on BenchMark XT compared to the PD-L1 IHC 22C3 pharmDx kit for urothelial carcinoma (UC) and head and neck squamous cell carcinoma (HNSCC)
    Vainer, G.
    Neuman, T.
    Fellig, Y.
    Meir, K.
    Hirshoren, N.
    Gofrit, O.
    Huang, L.
    Juco, J.
    Bal, T.
    VIRCHOWS ARCHIV, 2019, 475 : S95 - S95
  • [6] A Comparative Study of PD-L1 IHC 28-8 pharmDx and PD-L1 IHC 22C3 pharmDx on Malignancies from the Lung
    Skov, Birgit
    Skov, Torsten
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S815 - S816
  • [7] Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx
    Kalpakolf, Megan
    Hung, Stephanie
    Musser, Jeanette
    Roach, Charlotte
    Apostolaki, Angeliki
    Vilardo, Monika
    Peltz, Lindsay
    Watts, Brittany
    LaPlaca, Chris
    Tabuena-Frolli, Siena
    DiMaio, Michael A.
    Welcher, Rosanne
    Kulangara, Karina
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (09) : 667 - 673
  • [8] PD-L1 IHC 22C3 pharmDx: Analytical validation on cervical cancer specimens
    Musser, J.
    Evans, T.
    Posch, A.
    Vasquez, J.
    Tabuena-Frolli, S.
    Apostolaki, A.
    Kulangara, K.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S109 - S109
  • [9] HIGH SCORING PRECISION DEMONSTRATED IN MULTIPLE TUMOR INDICATIONS STAINED WITH PD-L1 IHC 22C3 PHARMDX USED IN CONJUNCTION WITH COMBINED POSITIVE SCORE
    Hand, Julia
    Ponce, Francisco
    Hund, Stephanie
    Peltz, Lindsay
    Adams, Micki
    Moquin, Deanna
    Kalpakoff, Megan
    Tabuena-Frolli, Siena
    Milo, Jay
    Apostolaki, Angeliki
    Kulangara, Karina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A76 - A76
  • [10] High staining reproducibility and scoring precision demonstrated in endometrial cancer stained with PD-L1 IHC 22C3 pharmDx used in conjunction with combined positive score
    Hand, Julia
    Morones, Amber
    Moquin, Deanna
    Martyniuk, Kelly
    Kalpakoff, Megan
    Tabuena-Frolli, Siena
    Milo, Jay
    Hund, Stephanie
    CANCER RESEARCH, 2024, 84 (06)
12345